Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GITMO-PHYLOS: Post-Transplant Cyclophosphamide for GvHD Prophylaxis in Mismatched HSCT
NCT03270748Phase 2Completed
- Sponsor
- GITMO
- Start
- Jan 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by GITMO. Started Jan 2020; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03270748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270748.